Comparison between Ambey Laboratories IPO and Nephro Care IPO.
Ambey Laboratories IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Nephro Care IPO is a SME Bookbuilding proposed to list at NSE SME.
| Ambey Laboratories IPO | Nephro Care IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | NSE SME | NSE SME |
| Lead Managers | Novus Capital Advisors Private Limited | Corporate Capitalventures Pvt.Ltd. |
| Registrar | MUFG Intime India Pvt.Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | Nikunj Stock Brokers Ltd. | SS Corporate Securities Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | Anchor Investor |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Ambey Laboratories IPO is up to ₹42.43 Cr whereas the issue size of the Nephro Care IPO is up to ₹39.18 Cr. The final issue price of Ambey Laboratories IPO is ₹68.00 per share and of Nephro Care IPO is ₹90.00 per share.
| Ambey Laboratories IPO | Nephro Care IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹65.00 per share | ₹85.00 per share |
| Issue Price (Upper) | ₹68.00 per share | ₹90.00 per share |
| Issue Price (Final) | ₹68.00 per share | ₹90.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹0.00 per share | |
| Market Lot Size | 2000 shares | 1600 shares |
| Fresh Issue Size | 59,28,000 shares | 43,53,600 shares |
| Fresh Issue Size (Amount) | up to ₹40.31 Cr | up to ₹39.18 Cr |
| OFS Issue Size | 3,12,000 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹2.12 Cr | up to ₹0.00 Cr |
| Issue Size Total | 62,40,000 shares | 43,53,600 shares |
| Issue Size Total (Amount) | up to ₹42.43 Cr | up to ₹39.18 Cr |
Ambey Laboratories IPO opens on Jul 04, 2024, while Nephro Care IPO opens on Jun 28, 2024. The closing date of Ambey Laboratories IPO and Nephro Care IPO is Jul 08, 2024, and Jul 02, 2024, respectively.
| Ambey Laboratories IPO | Nephro Care IPO | |
|---|---|---|
| Anchor Bid Date | Jul 03, 2024 | Jun 27, 2024 |
| Issue Open | Jul 04, 2024 | Jun 28, 2024 |
| Issue Close | Jul 08, 2024 | Jul 02, 2024 |
| Basis Of Allotment (Tentative) | Jul 09, 2024 | Jul 03, 2024 |
| Initiation of Refunds (Tentative) | Jul 10, 2024 | Jul 04, 2024 |
| Credit of Share (Tentative) | Jul 10, 2024 | Jul 04, 2024 |
| Listing date (Tentative) | Jul 11, 2024 | Jul 05, 2024 |
| Anchor Lockin End date 1 | Aug 08, 2024 | Aug 02, 2024 |
| Anchor Lockin End date 2 | Oct 07, 2024 | Oct 01, 2024 |
Ambey Laboratories IPO P/E ratio is 27.81, as compared to Nephro Care IPO P/E ratio of 55.15.
| Ambey Laboratories IPO | Nephro Care IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)
| Company Financials (Restated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 94.97 | 85.02 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 69.9 | 61.39 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 27.81 | 55.15 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹171.64 Cr. | ₹148.38 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 20.80% | 41.57% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 13.14% | 36.56% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.58 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹2.44 | ₹1.63 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 20.80% | 24.42% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Ambey Laboratories IPO Retail Individual Investors (RII) are offered 21,84,000 shares while in Nephro Care IPO retail investors are offered 21,84,000 shares. Qualified Institutional Buyers (QIB) are offered 12,48,000 shares in Ambey Laboratories IPO and 8,25,600 shares in Nephro Care IPO.
| Ambey Laboratories IPO | Nephro Care IPO | |
|---|---|---|
| Anchor Investor Reservation | 18,72,000 shares | 12,38,400 shares |
| Market Maker Reservation | 3,30,000 shares | 2,30,400 shares |
| QIB | 12,48,000 shares | 8,25,600 shares |
| NII | 9,36,000 shares | 6,19,200 shares |
| RII | 21,84,000 shares | 14,44,800 shares |
| Employee | 2,25,600 shares | |
| Others | ||
| Total | 62,40,000 shares | 43,53,600 shares |
Ambey Laboratories IPO subscribed 173.18x in total, whereas Nephro Care IPO subscribed 715.78x.
| Ambey Laboratories IPO | Nephro Care IPO | |
|---|---|---|
| QIB (times) | 61.90x | 245.14x |
| NII (times) | 324.22x | 1,787.19x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 195.06x | 634.12x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 173.18x | 715.78x |
